Core Viewpoint - The company, Nanjing Mairande Medical Technology Co., Ltd., is conducting a differentiated profit distribution plan, which includes a share buyback and a cash dividend distribution to shareholders [1][2][5]. Group 1: Share Buyback Plan - The company approved a share buyback plan on August 22, 2023, with a total fund of no less than RMB 20 million and no more than RMB 40 million, at a maximum price of RMB 50 per share [1]. - As of the date of the verification opinion, the company has repurchased 2,192,143 shares, accounting for 2.19% of the total share capital of 100 million shares [2][3]. Group 2: Profit Distribution Plan - The company plans to distribute a cash dividend of RMB 4.00 per 10 shares (including tax) to shareholders, with the total number of shares participating in the distribution being 97,807,857 shares after excluding the repurchased shares [2][4]. - The total cash dividend to be distributed amounts to RMB 39,123,142.80 (including tax) [3][4]. Group 3: Impact on Share Price - The reference price for ex-dividend trading is calculated based on the previous closing price minus the cash dividend, resulting in an ex-dividend reference price of approximately RMB 28.32 per share [4]. - The impact of the differentiated distribution on the ex-dividend reference price is minimal, with an absolute value change of less than 1% [4]. Group 4: Compliance and Verification - The sponsor institution, Nanjing Securities Co., Ltd., confirms that the differentiated profit distribution plan complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [5].
麦澜德: 南京证券股份有限公司关于南京麦澜德医疗科技股份有限公司差异化权益分派事项的核查意见